{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for theophylline in Standardized Name (approximate match)
Status:
First approved in 1950
Class (Stereo):
CHEMICAL (RACEMIC)
Status:
US Previously Marketed
First approved in 1943
Class (Stereo):
CHEMICAL (RACEMIC)
Conditions:
MERALLURIDE ACID is an organomercuric compound. It was used as a diuretic in a 1:1 mixture with theophylline.
Status:
Possibly Marketed Outside US
Source:
Theodrenaline by ZYF Pharm Chemical
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
THEODRENALINE, a theophylline derivative, is a cardiac stimulant. A 20:1 mixture of cafedrine and THEODRENALINE (AKRINOR®) is widely used in Germany for the treatment of hypotensive states during anesthesia and in emergency medicine.
Status:
Possibly Marketed Outside US
Source:
Teonicon by Bracco [Italy]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
There are a few information in the literature about pimephylline nicotinate. The metabolites of this compound were determined in the rats.
Status:
Possibly Marketed Outside US
Source:
Japan:Diisobutylaminobenzoyloxypropyl Theophylline
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Xanthine derivative, diisobutylaminobenzoyloxypropyl theophylline (Vestphyllin), is a vasodilator, bronchodilator.
Status:
Possibly Marketed Outside US
Source:
NCT03388853: Phase 4 Interventional Completed COPD
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Doxofylline (7-(1, 3-dioxalan-2-ylmethyl) theophylline) is a novel xanthine bronchodilator which differs from theophylline in that it contains a dioxalane group in position 7. Doxofylline is indicated for the treatment of bronchial asthma, pulmonary disease with spastic bronchial component and Chronic Obstructive Pulmonary Disease (COPD). Doxofylline does not directly inhibit any of the known HDAC enzymes, and did not inhibit any phosphodiesterase (PDE) enzyme sub types or act as an antagonist at any of the known adenosine receptors, except for PDE2A(1), and adenosine A(2A) and only at the highest tested concentration (10(-4) M). Doxofylline has greatly decreased affinity towards adenosine A1 and A2 receptors, which explain its better safety profile. Moreover, it does not interfere with calcium influx into the cells nor antagonize calcium channel blockers. Doxofylline has been shown to be a more potent bronchodilator with fewer side effects than theophylline. This drug should not be administered together with other xanthine derivatives, including beverages and foods containing caffeine.
Status:
Possibly Marketed Outside US
Source:
Bronchodil by Berlimed [UK]
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Reproterol is a short-acting β2 adrenoreceptor agonist used in the treatment of asthma. Reproterol increases the generation of cAMP in isolated peripheral blood monocytes in vitro more effectively than does orciprenaline. In the presence of the highly potent but nonselective ß-antagonist, propranolol, the cAMP-generating action of reproterol was inhibited only partially. Reproterol has gained wide use when it was licensed as a fixed combination therapy with cromoglycate. Until today, the bronchodilator effects of reproterol and the bronchoprotective and anti-inflammatory actions of cromoglycate combined in one inhaler remain the successful fixed combination of a disease-modifying and symptomatic drug for the treatment of asthma.
Status:
Possibly Marketed Outside US
Source:
Praxinor by Merck Lipha Sante
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Cafedrine, also known as norephedrinoethyltheophylline, is a chemical linkage of norephedrine and theophylline and is a cardiac stimulant used to increase blood pressure in people with hypotension. There are few data available for cafedrine. Cafedrine has a half-life of 60 min following both oral and intravenous administration Cafedrine is metabolized to norephedrine and several minor metabolites, but nearly 90% of the administered norephedrine is excreted via the kidneys, mostly unchanged, within 24 h. The effects of cafedrine on cardiac output are believed to be mediated via β- adrenoceptors. Cafedrine has a positive inotropic effect in humans, and this can be abolished by administration of the non-selective β-adrenoceptor antagonist propranolol. A combination of cafedrine and theodrenaline called Akrinor® is used for the treatment of hypotension in adults that occurs during emergency situations, general anesthesia, and regional anesthesia, especially during cesarean sections. Cafedrine/theodrenaline may have advantages over other vasopressor drugs. For example, it can be administered via bolus while catecholamines normally need to be diluted and administered via syringe pumps. Bolus injection is faster, which may be beneficial in emergency situations, plus it is more cost efficient with respect to the disposables. Cafedrine/theodrenaline has been widely used in Germany since 1963
Status:
Possibly Marketed Outside US
Source:
Dalophylline
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Etamiphylline is the respiratory stimulant. No information is available about pharmacodynamics of etamiphylline. No human pharmacokinetic data are available. Etamiphylline seems to be a rather weaker bronchodilator than theophylline when administered orally.
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
Proxyphylline is a xanthine derivative that acts as a cardiac stimulant, vasodilator and bronchodilator. In combination with ephedrine it’s used for relief of acute bronchial asthma and for reversible bronchospasm associated with chronic bronchitis and emphysema. Proxyphylline is readily absorbed from the gastrointestinal tract and it’s not converted to theophylline in the body. The clinical studies are agreed with the property of proxyphylline to inhibit the cyclic nucleotide phosphodiesterases.